NuVasive(R) Announces Conference Call and Webcast of First Quarter 2013 Results

NuVasive(R) Announces Conference Call and Webcast of First Quarter 2013 Results 
SAN DIEGO, CA -- (Marketwired) -- 04/16/13 --  NuVasive, Inc.
(NASDAQ: NUVA), a medical device company focused on developing
minimally disruptive surgical products and procedures for the spine,
announced details today relating to its first quarter 2013 earnings
announcement, which will take place on Tuesday, April 30, 2013, after
the close of the market.  
NuVasive will hold a conference call on Tuesday, April 30, 2013 at
5:30 p.m. ET / 2:30 p.m. PT to discuss the results. The dial-in
numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470
for international callers. A live webcast of the conference call will
be available online from the investor relations page of the Company's
corporate website at www.nuvasive.com.  
After the live webcast, the call will remain available on NuVasive's
website, www.nuvasive.com through May 31, 2013. In addition, a
telephone replay of the call will be available until May 14, 2013.
The replay dial-in numbers are 1-877-870-5176 for domestic callers
and 1-858-384-5517 for international callers. Please use pin number:
410865. 
About NuVasive
 NuVasive is a medical device company focused on
developing minimally disruptive surgical products and procedurally
integrated solutions for the spine. The Company is the 4th largest
player in the $8.2 billion global spine market. NuVasive's principal
product offering is based on its Maximum Access Surgery, or MAS(R)
platform. The MAS platform combines several categories of solutions
that collectively minimize soft tissue disruption during spine
surgery with maximum visualization and safe, easy reproducibility for
the surgeon: a proprietary software-driven nerve avoidance system and
intra-operative monitoring support; MaXcess(R), a unique split-blade
retractor system; a wide variety of specialized implants; and several
biologic products to aid in the spinal fusion process. MAS
significantly reduces surgery time and returns patients to activities
of daily living much faster than conventional approaches. Having
redefined spine surgery with the MAS platform's lateral approach,
known as eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has
built an entire spine franchise. With over 80 produc
ts today spanning
lumbar, thoracic and cervical applications, the Company will continue
to expand and evolve its offering predicated on its R&D focus and
dedication to outstanding service levels supported by a culture of
Absolute Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties are described in NuVasive's press
releases and periodic filings with the Securities and Exchange
Commission. NuVasive's public filings with the Securities and
Exchange Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect events
or circumstances arising after the date on which it was made. 
Contact:
Michael J. Lambert 
EVP & Chief Financial Officer 
NuVasive, Inc.
858-909-3394 
investorrelations@nuvasive.com 
Investor Contact:
Stephan Ogilvie 
VP, Corporate Development & Investor Relations
NuVasive, Inc.
201-322-6515
investorrelations@nuvasive.com  
Media: 
Nicole E. Collins
NuVasive, Inc.
858-909-1907
media@nuvasive.com 
 
 
Press spacebar to pause and continue. Press esc to stop.